US Patent and Trademark Office (USPTO) on December 6, 2011 has issued US Patent No. 8,071,551entitled "Methods and compositions for treating diabetes,” (Diabetes Patent) to Denver, Colorado-based Omni Bio Pharmaceutical, Inc. (Omni Bio).This patent expires in May 2022.

The Diabetes Patent is the most recently issued patent that Omni Bio licenses under agreements with the University of Colorado Denver and a private company. The Diabetes Patent claims a method for treating diabetes in subjects by administering an effective amount of a composition comprising Alpha-1 antitrypsin (AAT) or a derivative of AAT. AAT is an FDA-approved drug currently prescribed for chronic lung disease in AAT-deficient patients. The Diabetes Patent and other patents and patent applications that Omni Bio licenses cover methods of use for the treatment of new indications using AAT.

Dr. James Crapo, CEO of Omni Bio, commented, "We are extremely excited about the issuance of the Diabetes Patent, which combined with our initial Type 1 diabetes human clinical trial, we believe will potentially afford Omni Bio a commercial opportunity. It further reinforces our belief that AAT, through its anti-inflammatory properties, may be highly effective in the treatment of diabetes and other inflammatory diseases." Type 1 diabetes is also commonly referred to as juvenile diabetes.

Omni Bio has recently updated its corporate website to include current videos from Dr. Crapo and Dr Charles Dinarello, chief scientific officer of Omni Bio.

Omni Bio Pharmaceutical, Inc. is a clinical-stage biopharmaceutical company that has licensed potential new indications for an existing FDA approved drug – Alpha-1 antitrypsin (AAT). Omni Bio's core technology is based on issued patents and patent applications licensed from the University of Colorado Denver (UCD) and a privately held company.